Virtus Investment Advisers’s Ascendis Pharma A/S ASND Stock Holding History

Virtus Investment Advisers’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.42M	Buy	5,333 +1,503	+39%	+$351K	0.33%	131
2026 Q1	$876K	Buy	3,830 +730	+24%	+$164K	0.24%	157
2025 Q4	$661K	Buy	3,100 +500	+19%	+$103K	0.18%	198
2025 Q3	$517K	Hold	2,600	–	–	0.15%	203
2025 Q2	$449K	Sell	2,600 -147	-5%	-$23.9K	0.15%	196
2025 Q1	$428K	Buy	+2,747	New	+$392K	0.12%	205

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Virtus Investment Advisers's ASND Position: Q2 2026 in Review

Virtus Investment Advisers increased its Ascendis Pharma A/S (ASND) stake by 39% in Q2 2026, buying an estimated $351K and bringing the position to 5,333 shares worth $1.42M. The position accounts for 0.33% of the portfolio, ranked #131.

Virtus Investment Advisers first reported a position in ASND in Q1 2025 and has held it in 6 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Virtus Investment Advisers held 5,333 shares of Ascendis Pharma A/S worth $1.42M as of Q2 2026.
Virtus Investment Advisers bought 1,503 Ascendis Pharma A/S shares in Q2 2026, an estimated $351K.
Ascendis Pharma A/S made up 0.33% of Virtus Investment Advisers's portfolio in Q2 2026, its #131 holding.
Virtus Investment Advisers first reported a position in Ascendis Pharma A/S in Q1 2025 and has held it in 6 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.